Journal article
Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
European journal of haematology, Vol.113(6), pp.817-823
12/2024
DOI: 10.1111/ejh.14293
PMID: 39189919
Abstract
Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T-cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T-cell therapy. Cytokine release syndrome was seen in 75% of patients (grade ≥3: 0%) and immune effector cell-associated neurotoxicity syndrome (grade 1) in only one patient. Low-grade cytopenias were common (any grade/grade ≥3: neutropenia 62.5%/37.5%, anemia 37.5%/0%, thrombocytopenia 25%/0%). CAR T-cell therapy led to rapid and deep responses with a median time to best response of 43 days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T-cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis.Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T-cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T-cell therapy. Cytokine release syndrome was seen in 75% of patients (grade ≥3: 0%) and immune effector cell-associated neurotoxicity syndrome (grade 1) in only one patient. Low-grade cytopenias were common (any grade/grade ≥3: neutropenia 62.5%/37.5%, anemia 37.5%/0%, thrombocytopenia 25%/0%). CAR T-cell therapy led to rapid and deep responses with a median time to best response of 43 days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T-cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis.
Details
- Title: Subtitle
- Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
- Creators
- Utkarsh Goel - Cleveland ClinicDanai Dima - Cleveland ClinicJames Davis - Medical University of South CarolinaNausheen Ahmed - University of Kansas Medical CenterHira Shaikh - University of IowaJonathan Lochner - University of IowaAl-Ola Abdallah - University of Kansas Medical CenterJack Khouri - Cleveland ClinicHamza Hashmi - Memorial Sloan Kettering Cancer CenterFaiz Anwer - Cleveland Clinic
- Resource Type
- Journal article
- Publication Details
- European journal of haematology, Vol.113(6), pp.817-823
- Publisher
- Wiley
- DOI
- 10.1111/ejh.14293
- PMID
- 39189919
- ISSN
- 1600-0609
- eISSN
- 1600-0609
- Language
- English
- Electronic publication date
- 08/27/2024
- Date published
- 12/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984699524302771
Metrics
17 Record Views